Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) EBITDA: 2013-2017

Historic EBITDA for Tvardi Therapeutics (TVRD) over the last 5 years, with Sep 2017 value amounting to -$12.4 million.

  • Tvardi Therapeutics' EBITDA fell 7.16% to -$12.4 million in Q3 2017 from the same period last year, while for Sep 2017 it was -$65.9 million, marking a year-over-year decrease of 47.04%. This contributed to the annual value of -$57.2 million for FY2016, which is 131.51% down from last year.
  • Tvardi Therapeutics' EBITDA amounted to -$12.4 million in Q3 2017, which was down 32.71% from -$9.3 million recorded in Q2 2017.
  • Tvardi Therapeutics' 5-year EBITDA high stood at $6.9 million for Q2 2013, and its period low was -$22.2 million during Q1 2017.
  • For the 3-year period, Tvardi Therapeutics' EBITDA averaged around -$11.4 million, with its median value being -$10.7 million (2016).
  • As far as peak fluctuations go, Tvardi Therapeutics' EBITDA slumped by 153.65% in 2014, and later rose by 28.39% in 2017.
  • Over the past 5 years, Tvardi Therapeutics' EBITDA (Quarterly) stood at -$2.1 million in 2013, then tumbled by 105.99% to -$4.3 million in 2014, then slumped by 120.60% to -$9.6 million in 2015, then tumbled by 129.89% to -$22.0 million in 2016, then decreased by 7.16% to -$12.4 million in 2017.
  • Its EBITDA was -$12.4 million in Q3 2017, compared to -$9.3 million in Q2 2017 and -$22.2 million in Q1 2017.